Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis

Journal of Neuroimmunology

Volumn 102, Issue 1, 2000, Pages 26-31

  Achiron, Anat ^a   Miron, Shmuel ^a   Lavie, Vered ^b   Margalit, Raanan ^c   Biegon, Anat ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b PHARMOS LTD   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Animal model; EAE; Multiple sclerosis; Relapse; TNF inhibition

Indexed keywords

CANNABINOID; DEXANABINOL;

ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; ENCEPHALOMYELITIS; FEMALE; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT DISEASE;

ACUTE DISEASE; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED LEW; RECURRENCE; SPINAL CORD; TETRAHYDROCANNABINOL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033992335     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00149-6     Document Type: Article

References (27)

1. Bar Joseph A., Berkovitch Y., Adamchik J., Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. 23:1994;125-135.
2. Bass R., Trembovler V., Engelhard D., Shohami E. A novel non-psychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J. Infect. Dis. 173:1996;735-738.
3. Belayev L., Busto R., Watson B.D., Ginsberg M.D. HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study. Brain Res. 702:1995;266-270.
4. Belayev L., Busto R., Zhao W., Ginsberg M.D. HU-211, a novel non-competitive NMDA antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 26:1995;2313-2320.
5. Biegon A., Belayev L., Bendel P., Novikov M., Bass R., Shohami E. MRI study of rat brain edema after head trauma: effects of HU-211, a nonpsychotropic cannabinoid. Am. Soc. Neurosci. Abstr. 19:1993;1485.
6. Brewster M.E., Pop E., Foltz R., Reuschel S., Griffin W., Amselem S., Biegon A. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. 35:1997;361-365.
7. Burnette-Curley D., Cabral G.A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta-9-tetrahydrocannabinol. Proc. Soc. Exp. Biol. Med. 210:1995;64-76.
8. Eshhar N., Striem S., Kohen R., Tirosh O., Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283:1995;19-29.
9. Feigenbaum J.J., Bergmann F., Richmond S.A., Mechoulam R., Nadler V., Kloog Y., Sokolovsky M. Nonpsychotrophic cannabinoid acts as a functional NMDA receptor blocker. Proc. Natl. Acad. Sci. U.S.A. 86:1989;9584-9587.
10. Frequin S.T., Lamers K.J., Barkhof F., Borm G.F., Hommes O.R. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol. Scand. 90:1994;105-110.
11. Gallily R., Yamin A., Waksman Y., Ovadia H., Weidenfeld J., Bar-Joseph A., Biegon A., Mechoulam R., Shohami E. Protection against septic shock and suppression of tumor necrosis factor a and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283:1997;918-924.
12. Hautecoeur P., Forzy G., Gallois P., Demirbilek V., Feugas O. Variations of IL-2, IL-6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol. Belg. 97:1997;240-243.
13. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., Bornstein M.B. Delta 9 tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23:1989;73-81.
14. Martin R., McFarland H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32:1995;82-121.
15. Mechoulam R., Feigenbaum J.J., Lander N., Segal M., Jarbe T.U.C., Hiltunen A.J., Consroe P. Enantiomeric cannabinoids: stereo specificity of psychotropic activity. Experientia. 44:1988;762-764.
16. Mechoulam R., Lander N., Breuer A., Zahalka J. Synthesis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry. 1:1990;315-319.
17. Milligan N.M., Newcombe R., Compston D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol., Neurosurg. Psychiatry. 50:1987;511-516.
18. Nadler V., Mechoulam R., Sokolovsky M. The non-psychotropic cannabinoid (+)-(3s,4s)-7-hydroxy-delta 6-tetrahydrocannabinol 1,1,dimethylheptyl (HU-211) attenuates NMDA receptor mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. 159:1993;1-3.
19. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology. 45:1995;S11-S15. suppl. 6.
20. Philippe J., Debruyne J., Leroux-Roels G., Willems A., Dereuck J. In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis. Clin. Neurol. Neurosurg. 98:1993;286-290.
21. Raine C.S. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol. 36:1994;S61-S72. Suppl.
22. Shohami E., Novikov M., Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma. 10:1993;109-119.
23. Shohami E., Novikov M., Bass R. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res. 674:1995;55-62.
24. Shohami E., Gallily R., Mechoulam R., Bass R., Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72:1997;169-177.
25. Van Oosten B.W., Barkhof F., Scholten P.E., Von Blomberg B.M., Ader H.J., Polman C.H. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. Arch. Neurol. 55:1998;793-798.
26. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 28:1994;209-214.
27. Yoles E., Belkin M., Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma. 13:1996;49-57.